IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

AFFLICANT(s): Jose Esteve-Soler, et al.

SERIAL NO.: 10/536,782 ART UNIT:

FILING DATE: 11/23/05 EXAMINER:

TITLE: USE OF 2. 5-DIHYDROXYBENZENESULFONIC COMPOUNDS

FOR THE TREATMENT OF DISORDERS BASED ON AN IMPAIRMENT OF NO PRODUCTION AND/OR OF

REGULATION OF EDHF FUNCTION

ATTORNEY

DOCKET NO.: 785-012246-US (PAR)

Commissioner of Patents

F.O. Box 1450

Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT (37 C.F.R. §1.97(b) (3))

Sir:

This information disclosure statement is being filed before the mailing of a first Office Action on the merits.

The following information is being disclosed to the Patent and Trademark Office as information that may be material to the examination of the above-identified patent application. Applicants' Attorney is aware of the following reference:

"Metabolisme et pharmacocinetique du dobesilate de calcium chez l'Homme": ", A. Benakis, et al., Therapie, 1974, 29, 211-219

A copy of this reference is enclosed together with a Form PTO-1449. The filing of this Statement is not to be construed as a representation that a search has been made regarding the claimed invention (37 C.F.R. §1.97(g)) or that no other possible material information exists. In addition, the filing of this Information Disclosure Statement is not to be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability (37 C.F.R. §1.97(h)).

Respectfully submitted,

Geza C. Ziegler, Jr Reg. No. 44,004

PERMAN & GREEN, LLP 425 Post Road Fairfield, CT 068424 Customer No. 2512

DECASSIONS INVAMA

Approved for use through 0%36/2005 OMS 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/FTO	re required to respond to a collection of information unless it contains a valid OMB control number Complete if Known			
Southern to four seeds 10	Application Number	10/536,782		
INFORMATION DISCLOSURE	Filing Date	11/23/05 Jose Esteve-Soler, et al.		
STATEMENT BY APPLICANT	First Named Inventor			
	Art Unit			
(Use as many sheets as necessary)	Examiner Name			
Sheet 1 of 1	Attorney Dacket Number	785-012246-US (PAR)		

Examiner initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the Item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T2
		"Metabolisme et pharmacocinetique du dobesilate de calcium chez l'Homme(1)", A. Benakis, et al., Therapie, 1974, 29, 211-219	
			_

Examiner	Date	
Signature	Considered	

^{*}EXAMPLES: Insulid reference considered, whether or not obtain is conformance with MPEP 605. Draw like through disabon if not in conformance and not nenselessed include copy of this form with next communication to applicant

considered induside copy of this form with next commitmentation to applicant.

Applicants using to extraor extraor extraor extraor extraor. Applicant is not part to extraor e Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.